Abstract: Described herein are glycan compounds and particles comprising glycan compounds. The compounds and particles described herein are useful in methods of treating immune and inflammatory-related diseases.

Abstract: The present disclosure provides methods and compositions for modulating the activity of self-associated molecular pattern recognition receptors such as for example, Siglec (sialic-acid-binding immunoglobulin-type lectins) and complement factor H (CFH). Modulating the activity of infectious organisms such as viral influenza A, B, C, SARS-CoV1, 2, and cancer/tumor cells such as lung, breast and skin cancers. The compositions comprise a particle, comprising a molecule represented by the following structural formula: P-L-G, wherein P is a biocompatible polymer scaffold comprising at least one biocompatible polymer defined herein, G is a polysialic acid (PSA) comprising from 5 to 200 repeat units of sialic acid; and L is a covalent linker, or a pharmaceutically acceptable salt thereof.

Abstract: Described are compositions and methods for preventing, treating or ameliorating an inflammation-mediated and/or complement-mediated disease or condition in a subject comprising administering to the subject a Fas inhibitor, its derivative, a pharmaceutically acceptable salt thereof, or a gene therapy encoding the Fas inhibitor in an amount effective to inhibit Fas signaling.

Abstract: Described are compositions and methods for preventing, treating or ameliorating an inflammation-mediated and/or complement-mediated disease or condition in a subject comprising administering to the subject a Fas inhibitor, its derivative, a pharmaceutically acceptable salt thereof, of a gene therapy encoding the Fas inhibitor in an amount effective to inhibit Fas signaling.

Abstract: Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis. Also, described are compositions and methods for preventing, treating or ameliorating an inflammation-mediated and/or complement-mediated disease or condition in a subject comprising administering to the subject a Fas inhibitor, its derivative, a pharmaceutically acceptable salt thereof, of a gene therapy encoding the Fas inhibitor in an amount effective to inhibit Fas signaling.

Abstract: The invention is based on the realization that brain cancer cells spread preferentially along paths of elevated water diffusion, such as along nerve fiber bundles, that can be measured by magnetic resonance (MR) diffusion-weighted imaging (DWI) and the migration of cancer cells away from the primary tumor can be predicted using computational models that incorporate DWI information. The invention therefore applies DWI and models cell migration to develop appropriate non-symmetric margins for radiation treatment of malignant brain tumors.